#USA #New York #Class Action #Gross Law Firm #Novo Nordisk

Attention Novo Nordisk A/S Shareholders

In a significant legal development, The Gross Law Firm has reached out to shareholders of Novo Nordisk A/S (NYSE: NVO) regarding a pending class action lawsuit. This is particularly important for those who purchased shares during the defined class period, which spans from November 2, 2022, to December 19, 2024. Shareholders are encouraged to connect with the firm to discuss potential claims and the opportunity for a lead plaintiff position, although participation in recovery does not require this designation.

Allegations Against Novo Nordisk

The allegations center around a disappointing announcement made by Novo on December 20, 2024. The company publicized results from their REDEFINE 1 trial, associated with their new drug CagriSema, which intended to showcase its efficacy and safety over a 68-week duration. Despite expectations that patients would achieve at least a 25% weight loss, the actual results revealed a mere 22.7% decrease.

Adding to the concerns, the trial's structure allowed participants to adjust their dosages independently, which resulted in only 57.3% of those treated receiving the highest recommended dosage. This revelation led to a sharp decline in Novo's stock price, dropping by $18.44 per share, closing at $85.00. The financial impact on shareholders has urged many to seek redress through legal channels.

Key Dates and Next Steps

The Gross Law Firm has set a deadline of March 25, 2025, for shareholders to register for the class action. Interested parties should not delay as timely registration is essential to ensure participation. Once registered, shareholders will have access to a portfolio monitoring system that provides ongoing updates about the case's status.

The firm emphasizes that involvement comes at no cost or obligation to the shareholder. To register, individuals can visit their designated link or contact the firm directly for guidance.

Why Choose The Gross Law Firm?

Established as a nationally recognized class action law firm, The Gross Law Firm prioritizes the protection of investors from fraudulent or dishonest business practices. Their commitment involves advocating for responsible corporate behavior while seeking recoveries for investors suffering losses due to misleading statements or vital information omissions that led to overinflation of stock values.

For more information or queries, shareholders can reach out to The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Conclusion

For shareholders affected by the challenges surrounding Novo Nordisk’s stock performance, contacting The Gross Law Firm could be a crucial step in seeking restitution. As the deadline looms, taking action sooner rather than later is advisable to ensure participation in this significant class action lawsuit.